B. Riley Has Bearish Forecast for CGTX FY2025 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Analysts at B. Riley lowered their FY2025 earnings estimates for shares of Cognition Therapeutics in a report released on Thursday, February 6th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.87) for the year, down from their prior forecast of ($0.83). B. Riley currently has a “Buy” rating and a $1.50 price objective on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share.

A number of other equities research analysts also recently issued reports on CGTX. HC Wainwright boosted their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. Finally, Chardan Capital reissued a “buy” rating and set a $11.00 target price on shares of Cognition Therapeutics in a research report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Stock Down 2.5 %

CGTX stock opened at $0.58 on Monday. The company has a market cap of $24.28 million, a price-to-earnings ratio of -0.60 and a beta of 0.96. The business has a fifty day simple moving average of $0.65 and a 200-day simple moving average of $0.61. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. BIOS Capital Management LP acquired a new stake in Cognition Therapeutics during the 4th quarter valued at $4,208,000. Sigma Planning Corp boosted its position in Cognition Therapeutics by 211.6% in the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after buying an additional 417,300 shares during the last quarter. Virtu Financial LLC grew its stake in shares of Cognition Therapeutics by 40.1% during the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock valued at $56,000 after acquiring an additional 22,949 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Cognition Therapeutics during the fourth quarter worth about $26,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.